making thank Thank eventful and year XXXX and Ted. progress shaping you, objectives. Good us our be morning, which towards and a busy financial for are you today. up we joining for important everyone, corporate, is in to so clinical far Corbus,
system, a enzymes. to diseases. fibroid medicines associated as ECS, of two metabolic want it's the inflammatory, The is body's believe through body, our processes in targeting as regulator known vision remind so and ECS main a the of endocannabinoid We all potential that for provide these is what significant receptors GPCR and I company. master ligands the holds novel to you also
novel modulate preparing medications commercialize Since our discovering, potential developing potentially we now on that will have that this ECS system. for over options our targeting It treatment founding focused is powerful coming and the to belief XXXX, medicines decade in diseases. reshape many biological novel been the
into on year, we Annual Day York this further in City. held June this, XXst New provide Development and To insight Research our of
the I its highlighted we summarizing worthwhile three that topics think morning.
First, lenabasum.
advance updates clinical Chief they schedule. for to four continue the programs, our provide remain Dr. latest on We Officer our all each. White will Medical Barbara
Erythematosus. data to a along sclerosis We next systemic readout year, results remains top our fibrosis study and look the when Phase schedule line with from pivotal for on line studies Dermatomyositis cystic top Systemic Lupus XXXX. X forward in in
approach we licensing to successfully execute milestones partner As Pharmaceuticals, an payment, data to markets. double-digit Asia. forward lenabasum Earlier potentially our additional $XX deals for this we with royalties the a readouts, for million we Asian including million major with conducting on in We upfront look in agreements agreement sales future Kaken rights from year, a with and to continue in Japan potential vision in $XXX our other our lenabasum in commercial executed similar Japan.
launch company got expected Chief Day, people. right hiring Development following a lay Millian, begin as our year. earlier is the An was the some Craig growth important Officer step to this our of who groundwork with and meet the appointed of FDA in potential for commercial starts This our you've Commercial Research at to approval. the lenabasum to as
our Marketing. of us Brian head our We Brian EMD recently Walsh hired joins Serono. from as Global
served who of of most Chain We also Operations Global Regeneron. as recently our Kaizar Chain, Lehri, hired at Supply as Director Supply head
to as launching Affairs. Alnylam. appointed Quinn we A forward In key addition, Vice Dr. President been look from joined Medical Quinn Dinh the lenabasum. as the function us has of
in Business for Manufacturing at planning Executive XXXX. performance operations as operational Corbus to also most in Officer. Robert Development experience Dr. as recently the and years Vice Operations industry are Chief efficiency, will Operating Corbus, joined and more Bob than He Procurement CMC responsible optimizing of appointing President May be and biopharmaceutical Bristol-Myers of brings and XX Discordia We to company's new optimization. Squibb. development corporate business Director, role, In Bob his Pharmaceutical
later data topic Research demonstrated focused in fibrosis into and XXXX. CRB-XXXX a first-in-human enter our strong second number look testing in We case to Day use first a a our and as new year clinical forward has of drug therapeutic to inflammatory, metabolism, as preclinical its on inflammation models CRB-XXXX effect an Our for Development liver, fibrotic in forward for NASH. potential human investigational on plan that year. next such in study this provide moving diseases
our ECS proprietary preclinical activity our presented on with and distinct Discovery topic focused compounds platform. eight profiles. We Targeting Lastly, third structures
We portfolio. will future these for way enhance the property expect candidates drug and our pave clinical intellectual
further novel indications provides validation with to program our opens focusing of partners, on Discovery markets. and Our and potential collaborations the scientific approach door
Dr. call Barbara? to Medical White I'll Barbara turn that, over Officer. Chief With the our
